{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:34:08Z","timestamp":1792424048509,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijid.2024.107230","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T18:09:03Z","timestamp":1725473343000},"page":"107230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials"],"prefix":"10.1016","volume":"148","author":[{"given":"Lingyun","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.107230_bib0001","series-title":"Global tuberculosis report 2023","year":"2023"},{"key":"10.1016\/j.ijid.2024.107230_bib0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2024.107230_bib0003","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2024.107230_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00180-19","article-title":"The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2024.107230_bib0005","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2024.107230_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2024.107230_bib0007","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2024.107230_bib0008","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2024.107230_bib0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12879-021-05870-w","article-title":"Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial","volume":"21","author":"Weng","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2024.107230_bib0010","unstructured":"Zhang W-h. Refining MDR-TB treatment (T) regimens (R) for ultra(U) Short(S) therapy(T) (TB-TRUST). Clinicalstrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT03867136?term=NCT03867136&rank=1; 2023 [accessed 11 September 2023]."},{"key":"10.1016\/j.ijid.2024.107230_bib0011","unstructured":"Zhang W-h. Refining MDR-TB treatment (T) regimens (R) for ultra(U) Short(S) therapy, (T) PLUS (TB-TRUSTplus). Clinicalstrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT04717908?term=NCT04717908&rank=1; 2023 [acccessd 11 September 2023]."},{"key":"10.1016\/j.ijid.2024.107230_bib0012","unstructured":"HHS. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Washington: United States DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2017."},{"key":"10.1016\/j.ijid.2024.107230_bib0013","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2024.107230_bib0014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12916-018-1033-7","article-title":"Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study","volume":"16","author":"Tweed","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ijid.2024.107230_bib0015","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2024.107230_bib0016","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.gastro.2014.05.027","article-title":"Drug-induced liver injury: morbidity, mortality, and Hy's law","volume":"147","author":"Regev","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2024.107230_bib0017","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijid.2024.107230_bib0018","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1164\/rccm.201105-0850OC","article-title":"A comparison between two strategies for monitoring hepatic function during antituberculous therapy","volume":"185","author":"Singanayagam","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2024.107230_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12931-019-1256-y","article-title":"The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study","volume":"20","author":"Song","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.ijid.2024.107230_bib0020","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2024.107230_bib0021","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel: Chair: Panel members, EASL Governing Board representative:. EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2024.107230_bib0022","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","article-title":"Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines","volume":"15","author":"Devarbhavi","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijid.2024.107230_bib0023","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5588\/pha.23.0026","article-title":"Shorter TB treatment regimens should be safer as well","volume":"13","author":"Rucsineanu","year":"2023","journal-title":"Public Health Action"},{"key":"10.1016\/j.ijid.2024.107230_bib0024","article-title":"World Health Organization. WHO consolidated guidelines on tuberculosis: drug-resistant tuberculosis treatment","year":"2020","journal-title":"Geneva: World Health Organization"},{"key":"10.1016\/j.ijid.2024.107230_bib0025","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/cid\/ciy727","article-title":"Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: A retrospective cohort study","volume":"68","author":"Zhao","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2024.107230_bib0026","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2024.107230_bib0027","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (Stream stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2024.107230_bib0028","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5588\/ijtld.11.0591","article-title":"Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome","volume":"16","author":"Keshavjee","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2024.107230_bib0029","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5588\/ijtld.15.0668","article-title":"Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis","volume":"20","author":"Lee","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2024.107230_bib0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1440-1746.2012.07279.x","article-title":"Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury","volume":"28","author":"Devarbhavi","year":"2013","journal-title":"J Gastroenterol Hepatol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224003011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224003011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T13:57:52Z","timestamp":1729691872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224003011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"alternative-id":["S1201971224003011"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107230","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107230"}}